- CLINICAL BRIEFINGS
Comprehensive exploratory analyses of biomarkers were done in the phase III CheckMate 77T study of pre- and post-surgical treatment with the immunotherapy nivolumab in individuals with surgically resectable non-small-cell lung cancer. The analyses indicate that pre-surgical clearance of circulating tumour DNA, among other markers, is associated with improved clinical outcomes with nivolumab.
This is a summary of: Cascone, T. et al. Biomarkers of nivolumab benefit in resectable non-small cell lung cancer. Nature https://doi.org/10.1038/s41586-026-10925-6 (2026).
doi: https://doi.org/10.1038/d41586-026-02486-5
‘Expert opinion’ is published under a CC BY 4.0 licence; Figure 1 is published under a CC BY-NC-ND 4.0 licence.
References
Sung, H. et al. CA Cancer J. Clin. 76, e70090 (2026).
PubMed Google Scholar
Abbosh, C. et al. Nature 616, 553–562 (2023).
Article PubMed Google Scholar
Fick, C. N. et al. JTCVS Open 16, 9–16 (2023).
Article PubMed Google Scholar
Provencio, M. et al. Lancet Oncol. 25, 1453–1464 (2024).
Article PubMed Google Scholar
Provencio, M. et al. Nature Cancer 7, 169–181 (2026).
Article PubMed Google Scholar
Download references
Related Articles
-
Read the paper: Biomarkers of nivolumab benefit in resectable non-small cell lung cancer
-
Preoperative immune-therapy combination shows promise in skin cancer
-
Delivering an immune therapy into tumours instead of intravenously reduces adverse effects
Subjects
Latest on:
- Health care
- Cancer
-
Weight-loss drug slows ageing in female mice
News & Views
-
The nutritional value of invertebrate aquatic foods
Article
-
Charmed by comets
News & Views
-
Molecular mechanisms and pathogenesis of MASH
Review Article
-
Current therapeutic landscape and future treatment perspectives of MASH
Review Article
-
The Moderna cancer vaccine offers hope — now we must speed up personalized therapies
World View